Skip to main content
. Author manuscript; available in PMC: 2018 Feb 9.
Published in final edited form as: Vaccine. 2017 Dec 26;36(5):683–690. doi: 10.1016/j.vaccine.2017.12.046

Fig. 3.

Fig. 3

Vaccination-challenge experiments. Mice in experimental “VLPV groups” were primed with 5 ×106 FFU of VLPV1, VLPV2, or VLPV3 (blended formulation, VLPV1&VLPV2) and boosted 14days later with the same regimens. On Day 21, all mice were challenged with 1 × 103 PFU/dose of ML29 (intracranially), as previously described [25]. Mice immunized with a single dose of ML29 (1 × 103 PFU, SC) were used as a vaccine control group; mock-vaccinated animals were included in a challenge control group. (A), survival rate, %. (B), weight.